YAKUGAKU ZASSHI
The Pharmaceutical Society of Japan, established in 1880, is one of Japan’s oldest and most distinguished academic societies. The Society currently has around 18,000 members. It publishes three monthly scientific journals. Chemical and Pharmaceutical Bulletin (Chem. Pharm. Bull.) began publication in 1953 as Pharmaceutical Bulletin. It covers chemistry fields in the pharmaceutical and health sciences. Biological and Pharmaceutical Bulletin (Biol. Pharm. Bull.) began publication in 1978 as the Journal of Pharmacobio-Dynamics. It covers various biological topics in the pharmaceutical and health sciences. A fourth Society journal, the Journal of Health Science, was merged with Biol. Pharm. Bull. in 2012. Yakugaku Zasshi (Japanese for “Pharmaceutical Science Journal”) has the longest history, with publication beginning in 1881. Yakugaku Zasshi is published mostly in Japanese, except for some articles related to clinical pharmacy and pharmaceutical education, which are published in English.
The main aim of the Society’s journals is to advance the pharmaceutical sciences with research reports, information exchange, and high-quality discussion. The average review time for articles submitted to the journals is around one month for first decision. The complete texts of all of the Society’s journals can be freely accessed through J-STAGE. The Society’s editorial committee hopes that the content of its journals will be useful to your research, and also invites you to submit your own work to the journals.

Chairman of Committee
Ken-ichi Hosoya
Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama 
Read more
16,999 registered articles
(updated on January 21, 2019)
Online ISSN : 1347-5231
Print ISSN : 0031-6903
0.293
2017 IMPACT FACTOR
JOURNALS PEER REVIEWED FREE ACCESS ADVANCE PUBLICATION
Featured article
Volume 139 (2019) Issue 1 Pages 107-111
Therapeutic Effects of Intranasal Sumatriptan for Cluster Headache Read more
Editor’s picks

To clarify the associated factors for negative response to sumatriptan nasal spray (NS) in patients with cluster headache, we investigated the involvement of clinical information before commencing NS treatment. The efficacy of NS was 77.3% (n = 17) for these 22 patients. Three factors for negative response to NS, "young age of onset ", "psychiatric disorder", and "the headache is not in the orbit," were found. Therefore, these factors are considered to be useful for predicting therapy before applying NS.

View the past featured articles
View all articles in Current issue
Most viewed articles Dec.2018
Share this page
Select past volume & issue
feedback
Top